Axsome Therapeutics vs Collegium Pharmaceutical
Collegium Pharmaceutical is the larger business, with $781m of revenue in fiscal 2025 against $638m for Axsome Therapeutics (1.2 times as much). Axsome Therapeutics grew faster (65.5% against 23.6%). Collegium Pharmaceutical kept more of each dollar of sales as profit: a net margin of 8.1% against -28.7%. Collegium Pharmaceutical carries less debt relative to equity (79.0% against 212.6%).
| Latest fiscal year | Axsome TherapeuticsAXSM, 2025 | Collegium PharmaceuticalCOLL, 2025 |
|---|---|---|
| Revenue | $638m | $781m |
| Revenue growth | 65.5% | 23.6% |
| Net income | −$183m | $62.9m |
| Operating margin | -26.1% | 23.0% |
| Net margin | -28.7% | 8.1% |
| Return on equity | — | 23.7% |
| Free cash flow | −$93.9m | $328m |
| Cash | $323m | $231m |
| Total debt | $188m | $238m |
| Debt to equity | 212.6% | 79.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $25.1m |
| Employees | — | 423 |
| Market value | $7.38bn | $769m |
| Price vs our value range | — | Below our value range |
| Moat score | — | 48 (Moderate) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 14 sales |